TIDMSNG
RNS Number : 8998U
Synairgen plc
08 December 2021
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen Presents In Vitro Potency Data for Interferon Beta
Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for
Inhaled SNG001 at the 8(th) ESWI Influenza Conference
-- In vitro data demonstrate antiviral activity of SNG001
against multiple variants of SARS-CoV-2
-- Clinical biomarker data show inhaled SNG001 stimulates lung antiviral responses
Southampton, UK - 8 December 2021: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, a formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta for
the treatment of severe viral lung infections, has presented in
vitro and clinical data demonstrating antiviral activity for SNG001
in a poster and an oral presentation respectively at the 8(th)
European Scientific Working Group in Influenza (ESWI) Influenza
Conference, which was held virtually 4-7 December, 2021.
In the poster session, Synairgen presented in vitro data
demonstrating that SNG001, our formulation of the
naturally-occurring antiviral protein interferon beta, potently
reduced virus to undetectable levels in cells infected with
SARS-CoV-2 including the Alpha, Beta and Gamma variants of concern
(VOC), at concentrations that are readily achievable following
inhaled delivery of interferon beta.
"This study demonstrated potent antiviral activity of SNG001
against SARS-CoV-2 including Alpha, Beta and Gamma variants, which
is important given the continuing emergence and global spread of
variants of concern," Phillip Monk, Ph.D., Synairgen Chief
Scientific Officer, commented.
Synairgen is investigating the in vitro activity of SNG001
against the Delta and Omicron variants of SARS-CoV-2 and will make
data available as soon as possible.
In a separate oral session on 6 December, Dr Monk presented data
showing that inhaled SNG001 significantly increased interferon
beta-dependent antiviral biomarkers in the lungs of asthma and
chronic obstructive pulmonary disease (COPD) patients enrolled in
Phase 2 trials.
"SNG001 is an investigational drug currently in Phase 3 trials,
with the first data read out early in 2022, and contains the
essential antiviral protein interferon beta, a protein that
'switches on' antiviral defences. Interferon beta production by
lung cells is suppressed by the SARS-CoV-2 virus. We presented data
showing that SNG001 activates the lungs' antiviral defences for 24
hours after a dose has been delivered, supporting our once-a-day
dosing schedule," Dr Monk added.
Details of the two ESWI presentations are as follows:
Poster Presentation:
Title: Interferon beta has potent antiviral activity against
SARS-CoV-2 including variants of concern
Abstract: 269
Vero E6 cells, a cell line that is widely used in virology
studies, were pre-treated with SNG001 16 hours before, and
re-treated with SNG001 after, infection with 'Wuhan-like'
SARS-CoV-2, Alpha, Beta or Gamma variants. The presence of viral
protein-positive cells was determined 20 hours post-infection by
immunostaining.
The poster included the following data:
-- SNG001 potently reduced virus to undetectable levels
following infection of cells with 'Wuhan-like' SARS-CoV-2, Alpha,
Beta or Gamma variants.
-- SNG001 achieved 99% inhibition (IC99) at concentrations of
5.4, 17.7, 11.0 and 7.9 IU/mL respectively.
The poster presentation is available on the Synairgen website
.
Oral Presentation:
Title: Local delivery of interferon beta (SNG001) by inhalation
upregulates lung antiviral biomarkers
Abstract: 270
Sputum samples were collected from patients in two Phase 2
studies of SNG001: SG005 ( NCT01126177 ) in patients with asthma,
and SG015 ( NCT03570359 ) in patients with COPD. Gene expression of
IFN-<BETA>-dependent antiviral biomarkers, MX1 and OAS1, in
cells in the sputum samples were measured by RT-qPCR.
The presentation included the following data:
-- Inhaled SNG001 significantly increased levels of interferon
beta-dependent antiviral biomarkers in the lungs of both patient
populations compared with pre-treatment levels.
-- Biomarker responses were similar in younger asthma patients
and older COPD patients at the same dose.
-- SNG001 was well tolerated.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014 ('MAR').
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Brooke.Clarke@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs. SNG001 has been granted Fast Track status from the US Food
and Drug Administration (FDA) and the Phase 3 SPRINTER trial was
deemed an Urgent Public Health study by the UK's National Institute
for Health Research (NIHR). Synairgen's Phase 3 clinical programme
is currently evaluating nebulised SNG001 in patients across 17
countries. In a Phase 2 trial in hospitalised COVID-19 patients,
SNG001 demonstrated a greater than two-fold chance of recovery to
'no limitation of activities' versus placebo.(1)
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
(1)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDBBDDSDGDGBR
(END) Dow Jones Newswires
December 08, 2021 02:00 ET (07:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
